A vaccine applying conserved SARS-CoV-2 epitopes that induce both memory CD8+ and CD4+ T-cell responses across different populations with various HLA allotypes might represent a promising tool to end the public health and economic burdens due to the COVID-19 pandemic. This evidence concerns the gene CD8A and COVID-19.